Keyphrases
Disease-modifying Therapy
100%
Relapsing-remitting multiple Sclerosis
100%
Tolerability
42%
Mechanism of Action
28%
Disease Severity
14%
Multiple Sclerosis
14%
Interferon-α (IFN-α)
14%
Disease Activity
14%
Clinical Care
14%
Natalizumab
14%
Patient Preference
14%
Treatment Algorithm
14%
Armamentarium
14%
Neurologist
14%
Disease Spectrum
14%
Safety Self-efficacy
14%
Number of Factors
14%
Glatiramer Acetate
14%
Decision Basis
14%
Fingolimod
14%
Individual Choice
14%
Dimethyl Fumarate
14%
Teriflunomide
14%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Multiple Sclerosis
100%
Tolerability
42%
Disease Severity
14%
Interferon
14%
Disease Activity
14%
Natalizumab
14%
Glatiramer
14%
Fingolimod
14%
Fumaric Acid Dimethyl Ester
14%
Teriflunomide
14%